Trial Profile
A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 May 2020
Price :
$35
*
At a glance
- Drugs Samelisant (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; First in man
- Sponsors Suven Life Sciences
- 12 May 2020 Results of NCT04072380 and NCT02342041 assessing Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, published in the Clinical Drug Investigation
- 20 Jul 2017 Results assessing safety, tolerability, and pharmacokinetics after single and multiple ascending doses in healthy adult subjects presented at the Alzheimer's Association International Conference 2017
- 19 Oct 2015 Results presented at the annual meeting of the Society for Neuroscience (SFN) 2015, as per Suven Life Science media release.